PredictImmune's £10m Series B round boosts IBD treatment

The crucial 12 months after diagnosis is a window of opportunity for disease treatment, says Paul Kinnon, CEO of PredictImmune, whose £10million Series B funding round has just closed.

Babraham Research Campus-based PredictImmune develops pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases. Its first product, PredictSURE IBD, is the world’s first, truly validated and CE-marked prognostic test for guiding treatment options in inflammatory bowel disease, or IBD, which includes Crohn’s disease and ulcerative colitis.

“We are now conducting tests in partnership with Addenbrooke’s,” Mr Kinnon told the Cambridge Independent. “It’s a very strategic challenge, working with gastroenterologists, and we’re now building a leadership position.